Genzyme Corporation (Nasdaq: GENZ) announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE